PPIDT00072

Drug Information
NameAlemtuzumab
SequenceQVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
DrugBank_IDDB00087
Typebiotech
IndicationLEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.[L43397] LEMTRADA contains the same active ingredient (alemtuzumab) found in CAMPATH, and CAMPATH is approved for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), although generally administered at higher and more frequent doses (e.g., 30 mg) than recommended in the treatment of MS.[L43397]
Dosage Forms
Form Route Strength
Injection Intravenous
30 mg/1mL
Injection, solution, concentrate Intravenous
12 mg/1.2mL
Injection, solution, concentrate Intravenous; Parenteral
12 MG
Solution Intravenous
12 mg / 1.2 mL
Solution Subcutaneous
12.0000 mg
Injection, solution, concentrate —
12 mg/1.2ml
Injection, solution, concentrate Intravenous
12 mg
Solution Intravenous
12 mg/1.2ml
Solution Intravenous
1200000 mg
Injection, solution, concentrate Intravenous
10 MG/ML
Solution Intravenous
10 mg / mL
Solution Intravenous
30 mg / mL
Solution, concentrate Intravenous
30 MG/ML
Solution Intravenous
3000000 mg
Solution Intravenous
30 mg/ml
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P31358 CD52 CAMPATH-1 antigen Homo sapiens antibody Link
target O75015 FCGR3B Low affinity immunoglobulin gamma Fc region receptor III-B Homo sapiens binder Link
target P08637 FCGR3A Low affinity immunoglobulin gamma Fc region receptor III-A Homo sapiens binder Link
target P12314 FCGR1A High affinity immunoglobulin gamma Fc receptor I Homo sapiens binder Link
target P12318 FCGR2A Low affinity immunoglobulin gamma Fc region receptor II-a Homo sapiens binder Link
target P31994 FCGR2B Low affinity immunoglobulin gamma Fc region receptor II-b Homo sapiens binder Link
target P31995 FCGR2C Low affinity immunoglobulin gamma Fc region receptor II-c Homo sapiens binder Link